Dr. Berdeja on Maintenance Therapy in Multiple Myeloma

Jesus Berdeja, MD
Published: Wednesday, Feb 06, 2019



Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Following stem cell transplant, maintenance therapy with lenalidomide (Revlimid) is the standard of care, says Berdeja. Although data from the PURPOSE trial have suggested that bortezomib (Velcade) can also be used in select patients, Bordeja cautions that the arm that received bortezomib maintenance also received bortezomib at the time of induction. Physicians are unsure of whether the benefit was due to the patient’s exposure to the proteasome inhibitor (PI) during induction, or their exposure to the PI during maintenance.

At the 2018 ASH Annual Meeting, a study was presented on maintenance with ixazomib (Ninlaro), adds Berdeja. For this trial, investigators set out to answer the question of whether or not a PI as maintenance therapy can improve progression-free survival and overall survival. Although the study follow-up is relatively short, there seems to be an improvement in PFS with maintenance ixazomib, says Bordeja, but whether or not it is superior to lenalidomide maintenance remains to be seen.
SELECTED
LANGUAGE


Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Following stem cell transplant, maintenance therapy with lenalidomide (Revlimid) is the standard of care, says Berdeja. Although data from the PURPOSE trial have suggested that bortezomib (Velcade) can also be used in select patients, Bordeja cautions that the arm that received bortezomib maintenance also received bortezomib at the time of induction. Physicians are unsure of whether the benefit was due to the patient’s exposure to the proteasome inhibitor (PI) during induction, or their exposure to the PI during maintenance.

At the 2018 ASH Annual Meeting, a study was presented on maintenance with ixazomib (Ninlaro), adds Berdeja. For this trial, investigators set out to answer the question of whether or not a PI as maintenance therapy can improve progression-free survival and overall survival. Although the study follow-up is relatively short, there seems to be an improvement in PFS with maintenance ixazomib, says Bordeja, but whether or not it is superior to lenalidomide maintenance remains to be seen.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x